Ehlers-Danlos Syndromes and hEDS: What Hypermobility Really Means

Short Answer

Ehlers-Danlos syndromes (EDS) are a group of inherited connective-tissue disorders — problems with the tissues that hold you together: skin, joints, blood vessels, bones, and organs. In many EDS types, the issue involves collagen or collagen-related pathways, so the body's "scaffolding" can be stretchier, more fragile, or less stable than expected. The most common form is hypermobile EDS (hEDS), where joints move beyond the usual range and can become painful, unstable, or prone to subluxations and dislocations; hypermobility spectrum disorder (HSD) is the related diagnosis used when symptomatic hypermobility is present but the full hEDS criteria are not met (medlineplus.gov).

Both hEDS and HSD are inherited disorders expected to display a "1:1 sex ratio," yet clinic populations often look very different: in one Mayo Clinic EDS Clinic cohort, 90.6% of hEDS patients were female, and the female-to-male ratio was 9.6:1 for hEDS and 19.6:1 for HSD. That gap may partly reflect who becomes symptomatic enough to seek care, and newer research is looking at sex-linked differences in mast-cell activity, extracellular-matrix remodeling, autonomic symptoms, and pain burden (pmc.ncbi.nlm.nih.gov).

hEDS also often travels with POTS, dysautonomia, and mast-cell activation symptoms — the overlap many patients call the "trifecta." In the body, that can feel like joints that do not hold steady, a heart rate that jumps when you stand, dizziness or near-fainting, flushing, hives, GI upset, fatigue, and pain that seems to move between systems instead of staying in one neat box. Studies and reviews describe these conditions as clinically associated, but they are not the same diagnosis, and having one does not automatically mean you have all three (ncbi.nlm.nih.gov).

There is no single blood test for hEDS. It is diagnosed clinically, using the 2017 international criteria: generalized joint hypermobility, systemic connective-tissue features and/or family history and musculoskeletal complications, plus exclusion of other conditions that could better explain the picture. Many rarer EDS subtypes have known genetic causes and are evaluated with genetic testing, but hEDS currently does not have a confirmed molecular test that can establish the diagnosis on its own (pubmed.ncbi.nlm.nih.gov).

Welltory does not diagnose EDS, hEDS, POTS, or hypermobility, and it is not a diagnostic test. But if your hypermobility comes bundled with racing-heart episodes, dizziness, poor recovery, fatigue, or "why is my body acting like an alarm system?" days, tracking pulse and HRV over time can make the autonomic pattern more visible — useful context to bring to a clinician, not a replacement for one.

Ehlers-Danlos syndromes at a glance

• What it is — Ehlers-Danlos syndromes are inherited connective-tissue conditions. The problem sits in the body's structural support system — the collagen-rich tissues that help hold skin, joints, blood vessels, bones, and internal organs together — so symptoms can show up in many places at once (medlineplus.gov).

• Number of types — The current international framework recognizes 13 EDS subtypes, including hypermobile, classical, and vascular EDS; this expanded 2017 classification added rarer forms that had been identified more recently (medlineplus.gov).

• Most common form — Hypermobile EDS (hEDS) is the most common EDS type; hypermobility spectrum disorder (HSD) is closely related and is used when symptomatic hypermobility is present but full hEDS criteria are not met. hEDS is still a clinical diagnosis: there is no single confirmatory gene test for it yet (medlineplus.gov).

• Core sign — The core physical sign is joint hypermobility — described as "the ability of one or more joints to move beyond the normal range of motion." That extra range can be painless for some people, but in hEDS/HSD it often comes with instability, subluxations, dislocations, soft-tissue injury, and chronic pain (pmc.ncbi.nlm.nih.gov).

• Screening tool — The Beighton score is a 9-point screen for generalized joint hypermobility. In the 2017 hEDS framework, commonly cited cutoffs are ≥6 before puberty, ≥5 from puberty through age 50, and ≥4 after age 50; the score is only one part of the full clinical criteria, not a diagnosis by itself (pmc.ncbi.nlm.nih.gov).

• Who it affects — Clinically diagnosed hEDS/HSD cohorts are strongly female-predominant. In one large Mayo Clinic series, 90.6% of hEDS patients were female and 9.4% were male, a sex ratio of 9.6:1 female-to-male; the same paper reported an even higher female-to-male ratio in HSD (pmc.ncbi.nlm.nih.gov).

• Common overlaps — The "bendiness" is only part of the story. hEDS/HSD commonly travels with multisystem symptoms such as POTS or other dysautonomia, chronic fatigue, functional gut symptoms, migraine, mast-cell activation-type inflammation, anxiety disorders, and fibromyalgia-like pain. Recent autonomic-clinic and hypermobility-cohort studies also describe overlap with MCAS, hives, ME/CFS, chronic pain, and ADHD (ncbi.nlm.nih.gov).

• Diagnosis — hEDS is diagnosed clinically against the 2017 international criteria: generalized joint hypermobility, additional systemic/family/musculoskeletal features, and exclusion of other explanations all matter. Genetic testing can confirm many other EDS subtypes, but not hEDS in routine care because its underlying gene or biomarker has not been established (pubmed.ncbi.nlm.nih.gov).

• Red flag subtype — Vascular EDS (vEDS) is the emergency red-flag subtype because fragile arteries and organs can lead to arterial dissection or rupture, internal bleeding, bowel or uterine rupture, and other life-threatening complications. Sudden severe chest, abdominal, back, or head pain; signs of stroke; collapse; or heavy unexplained bleeding need urgent medical care (my.clevelandclinic.org).

What are the Ehlers-Danlos syndromes?

The Ehlers-Danlos syndromes, or EDS, are a family of heritable connective-tissue disorders. Connective tissue is your body's scaffolding: it helps support your skin, bones, blood vessels, organs, and many other tissues. Much of that scaffolding depends on collagen and on proteins that process, fold, or interact with collagen. When EDS-related gene variants disrupt that system, the tissue meant to hold you together can become weaker, stretchier, or more fragile than it should be. That's why the same underlying connective-tissue problem can show up in several places at once: overly flexible ("hypermobile") joints, joints that feel unstable or dislocate, soft or stretchy skin, easy bruising, abnormal scarring or wound healing, and tissue or blood-vessel fragility (medlineplus.gov).

EDS is not one single condition. Under the 2017 international classification, there are 13 recognized EDS subtypes, each defined by a pattern of clinical features and, for most subtypes, a known genetic cause. The differences matter because the risks are not the same for every person: one subtype may mainly affect joints and skin, while another may carry higher concern for blood vessels or organs. So the name of the subtype is not just a label — it helps clinicians decide what to examine, what to monitor, and when a symptom should be treated as a red flag (pubmed.ncbi.nlm.nih.gov).

Hypermobile EDS (hEDS), HSD, and the Beighton score

Hypermobile EDS (hEDS) is the EDS subtype most people mean when they search for "heds." Its core feature is generalized joint hypermobility — described as "the ability of one or more joints to move beyond the normal range of motion" — but the diagnosis is not just about being bendy. hEDS is the bendiness plus what that extra motion does to the body over time: joint instability, chronic pain, subluxations or dislocations that can happen with little force, soft or mildly stretchy skin, and symptoms that may come from other systems too, including fatigue, functional bowel problems, dizziness or other autonomic complaints, migraine, and mast-cell-type symptoms. Unlike most other EDS subtypes, hEDS has no confirmed single gene or genetic test, so clinicians diagnose it from the 2017 clinical criteria and by ruling out other connective-tissue, rheumatologic, and neuromuscular conditions that can look similar (ncbi.nlm.nih.gov).

Hypermobility spectrum disorder (HSD) is the related label for people whose joints are hypermobile and symptomatic, but who do not meet the full hEDS criteria and do not have another specific diagnosis explaining the hypermobility. In real life, that can feel less like two separate boxes and more like neighboring points on the same clinical map: people with hEDS and HSD can both live with pain, instability, fatigue, gut symptoms, lightheadedness, and injury patterns that make ordinary movement more expensive for the body. A 2026 Mayo Clinic EDS Clinic study looked at 2,451 patients diagnosed with hEDS or HSD using the 2017 criteria and analyzed sex differences in 122 self-reported symptoms and comorbidities — a useful reminder that the 2017 framework defines the labels, but the lived symptom footprint can be wide (pmc.ncbi.nlm.nih.gov).

The Beighton score is the quick bedside screen for generalized hypermobility. It is a 9-point scale: one point for each little finger bending back beyond 90 degrees, each thumb touching the forearm, each elbow extending backward more than 10 degrees, each knee extending backward more than 10 degrees, and one point for placing both palms flat on the floor with knees straight. The 2017 hEDS criteria use age-based cutoffs — 6 or more out of 9 for prepubertal children and adolescents, 5 or more out of 9 from puberty through age 50, and 4 or more out of 9 after age 50; the adult GeneReviews summary lists the same adult thresholds, ≥5 through age 50 and ≥4 after 50. A high score supports generalized hypermobility, but it is only one part of the diagnosis: the full hEDS criteria also require systemic features, family history and/or musculoskeletal complications, and exclusion of alternative diagnoses (ncbi.nlm.nih.gov).

"Is hypermobility bad?" Not necessarily. Many hypermobile people never develop a medical problem; their joints simply move farther than average. Hypermobility becomes clinically important when that extra range comes with pain, repeated sprains, dislocations or subluxations, fatigue, bowel or bladder symptoms, dizziness or fainting, or the feeling that your body is working too hard to hold itself together. That is the "why" behind assessment: clinicians are not just measuring flexibility — they are looking for instability, tissue fragility, nervous-system strain, and the pattern of symptoms around the joints (my.clevelandclinic.org).

Who gets hEDS — sex, collagen, and the "1:1 that isn't"

EDS is inherited, and on paper the sexes should be affected equally: hEDS and HSD are inherited disorders expected to display a "1:1 sex ratio." In clinics, though, many people see a very different pattern: waiting rooms and support groups that feel overwhelmingly female. A large 2026 Mayo Clinic Florida EDS Clinic study looked at 2,451 adults diagnosed with hEDS or HSD using the 2017 criteria. In that clinic sample, 90.6% of hEDS patients were female and 9.4% were male — a sex ratio of 9.6:1 female-to-male. For HSD, the skew was even larger: 95.2% of HSD patients were female and 4.8% were male, with a sex ratio of 19.6:1 female-to-male. That does not prove the true population ratio is 10:1 or 20:1. It tells us who reached, and was diagnosed in, a specialty clinic. Biology, referral patterns, symptom burden, and diagnostic bias may all be in the mix (pmc.ncbi.nlm.nih.gov).

One mechanistic clue from the same study links mast cells and collagen. Females with HSD reported more mast cell-related symptoms (such as hives) than males, and the authors propose that elevated mast cell activity in females may lead to extracellular matrix remodeling that promotes hypermobility. In plain body terms: mast cells are immune cells that can release inflammatory mediators; connective tissue is constantly being broken down, repaired, and remodeled; and collagen-related extracellular matrix proteins help give that tissue structure. If mast-cell signaling is higher in some people, it could plausibly affect the tissue environment around joints. This is still a hypothesis — not a diagnostic test, and not proof that mast cells "cause" hEDS — but it gives researchers one way to connect female predominance, mast-cell symptoms, and connective-tissue biology (pmc.ncbi.nlm.nih.gov).

A separate 2026 electronic-health-record study in LGBT Health found a higher recorded prevalence of hEDS and HSD in transgender and gender-diverse (TGD) people than in cisgender comparison groups, reporting an odds ratio of 18.45 and concluding a substantially increased burden of hypermobility-related disorders among TGD individuals. The study also reported prevalence of 2.62% among TGD people assigned female at birth and 1.00% among TGD people assigned male at birth, compared with 0.16% and 0.04% in cisgender females and males. That finding is important for clinical recognition, but it should be read carefully: EHR studies can show an association in recorded diagnoses; they do not prove that gender identity causes hEDS or HSD (pubmed.ncbi.nlm.nih.gov).

The "trifecta": hEDS + POTS + mast-cell activation

hEDS rarely travels alone. Many patients describe a recurring cluster of hEDS + POTS (or another form of dysautonomia) + mast-cell activation syndrome (MCAS); in the medical literature, this is usually framed as a triad or comorbidity cluster rather than a single proven disease mechanism. That distinction matters. The overlap is real enough to shape symptoms and clinic visits, but the "why" is still being worked out: connective tissue affects joints, skin, blood vessels, and organs; POTS reflects trouble keeping heart rate, blood-vessel constriction, blood pressure, and blood flow steady when you stand; mast-cell activation can add flushing, hives, swelling, gut symptoms, and allergy-type flares on top (ncbi.nlm.nih.gov).

The research backs the individual links. On the autonomic side, a 2026 Mayo Clinic study in 2,451 adults diagnosed with hEDS or HSD found that more females than males were diagnosed with fibromyalgia and reported symptoms associated with autonomic dysfunction — placing dysautonomia, pain amplification, and fibromyalgia squarely inside the hypermobility symptom cluster. And an autonomic-testing study that compared long COVID and ME/CFS patients did so against a large hEDS reference group — 290 patients with hypermobile Ehlers-Danlos syndrome — because hEDS is so commonly studied in the same physiologic neighborhood: orthostatic intolerance, abnormal autonomic reflexes, small-fiber findings, fatigue, dizziness, and reduced upright blood flow (pmc.ncbi.nlm.nih.gov).

On the mast-cell side, a Johns Hopkins POTS-clinic study of the same neighborhood of conditions found that mast cell activation, often manifesting as hives, has been proposed as a contributing mechanism in dysautonomia, and measured that skin signal directly: among 188 respondents, 80 (42.6%) reported hives sometimes and 33 (17.6%) reported hives often or always. Its conclusion — that hives are common in orthostatic intolerance syndromes and are associated with increased symptom burden — is the clearest evidence for the mast-cell leg of the trifecta. It does not prove that hives equal MCAS, or that MCAS causes POTS. It does show that, in people already being evaluated for orthostatic intolerance, mast-cell-like skin symptoms can mark a heavier whole-body symptom load (pmc.ncbi.nlm.nih.gov).

Where a wearable fits. Welltory can't diagnose EDS, POTS, or MCAS. But for the large hypermobile group whose days are dominated by racing pulse on standing, dizziness, fatigue, heat intolerance, brain fog, and "why did my body crash today?" episodes, the autonomic layer is where a phone- or watch-based heart-rate and HRV log can help. It turns "I feel like my heart races when I stand" into a pattern you can see over weeks: morning vs. evening, after poor sleep, after a flare, after a walk, after a shower, after a stressful day. That is a POTS-adjacent contribution — context for the autonomic symptoms that often ride with hEDS — not an EDS test and not a mast-cell test (my.clevelandclinic.org).

Symptoms beyond the joints — skin, gut, fatigue, ADHD

Because connective tissue helps support your skin, bones, blood vessels, and many organs, EDS can feel like a body-wide condition rather than "just flexible joints." That is why the 2026 Mayo EDS Clinic study looked across 122 self-reported symptoms and comorbidities in people diagnosed with hEDS or HSD, instead of treating pain, fatigue, gut symptoms, autonomic symptoms, and neurodivergence as separate stories (pmc.ncbi.nlm.nih.gov). Common features people search for include:

• Skin (`heds skin`, `heds scars`/`heds scarring`). In hEDS, skin may be soft, mildly stretchy, bruise easily, or show atrophic scars; this is part of the connective-tissue picture, but it is not the same as the dramatic scarring pattern people often associate with EDS. Poor wound healing and wide, thin "cigarette-paper" scars are especially characteristic of classical EDS, while hEDS is usually described with milder skin hyperextensibility and without the unusual tissue fragility that should push a clinician to consider other EDS subtypes (ncbi.nlm.nih.gov).

• Face (`heds face`). There is no single diagnostic "hEDS face." Some people with hEDS have connective-tissue clues such as dental crowding, a high or narrow palate, or a marfanoid body shape, and some rarer EDS subtypes have more specific craniofacial features. But a face checklist from social media should not be treated as a diagnosis. hEDS is still a clinical diagnosis based on the 2017 criteria, and there is currently no single confirmed genetic test for it (ncbi.nlm.nih.gov).

• Joints. The joint symptoms are often the loudest: chronic pain, unstable joints, subluxations, dislocations, soft-tissue injury, and the feeling that your body has to "hold itself together" with muscle effort. Hypermobility can also change recovery from other problems. In a 2026 prospective study after metabolic and bariatric surgery, people without hypermobility had less pain in several load-bearing areas after weight loss, while the hypermobility group did not show the same improvement; the authors concluded that joint hypermobility limits pain improvement (pmc.ncbi.nlm.nih.gov).

• Fatigue, gut, and autonomic symptoms. Fatigue in hEDS can come from several places at once: muscles working harder to stabilize joints, poor sleep, chronic pain, autonomic dysfunction, or other overlapping conditions. Gut symptoms are also common and underrecognized — reflux, early fullness, delayed gastric emptying, IBS-type diarrhea or constipation, bloating, cramping, and pelvic/anorectal issues can travel with hEDS. Autonomic symptoms can show up as palpitations, chest discomfort, dizziness, near-fainting, postural hypotension, or postural tachycardia, which is why your heart rate and symptom timing can be useful context to bring to a clinician (ncbi.nlm.nih.gov).

• Neurodivergence (`hypermobility and adhd`). Hypermobility is reported alongside ADHD and autism more often than expected. GeneReviews notes that ADHD and autism are reported more frequently in people with hEDS, and a retrospective pediatric study of 201 children with HSD or hEDS found verified ADHD in 16%, another 7% under ADHD evaluation, and verified autism spectrum disorder in 6%. In the 2026 Mayo clinic series, ADHD/ADD, developmental delay, and autism were among the few features reported more often in males. The association is real in the data, but the "why" is not settled yet (pubmed.ncbi.nlm.nih.gov).

• Mental health and isolation. Living with a complex, often-dismissed condition takes a toll on the nervous system and on relationships. hEDS is associated with depression, anxiety, low confidence, hopelessness, and the strain of feeling misunderstood or marginalized in healthcare; qualitative work also describes how hEDS/HSD can change identity, social participation, family roles, and the ability to ask for help. A 2026 Journal of Health Psychology paper found that loneliness was the strongest and most consistent predictor of poorer outcomes, and framed it as a potent and modifiable risk factor (journals.sagepub.com).

How EDS is diagnosed — and who to see

There is no single blood test for hEDS. Hypermobile EDS is diagnosed by what your body shows over time: your joint range, your injury pattern, your skin and connective-tissue signs, your family history, your pain pattern, and what else has been ruled out. The diagnosis is clinical, made against the 2017 international diagnostic criteria. Those criteria require all 3 parts to fit at the same time: generalized joint hypermobility, usually measured with the Beighton score; additional systemic features, family history, and/or musculoskeletal complications; and exclusion of other connective-tissue, autoimmune, rheumatologic, neuromuscular, or skeletal conditions that could explain the same symptoms (ncbi.nlm.nih.gov).

The other EDS subtypes — classical, vascular, and many of the rarer forms — usually can be confirmed with genetic testing, because their causative genes are known. hEDS is the exception: GeneReviews states that no underlying genetic, epigenetic, or metabolomic cause has been identified for hEDS, so molecular genetic testing cannot establish the diagnosis. By contrast, classical EDS is confirmed by pathogenic variants such as COL5A1, COL5A2, or COL1A1, and vascular EDS is confirmed by a pathogenic variant in COL3A1 (ncbi.nlm.nih.gov).

Who diagnoses it (`EDS specialist near me`, `rheumatologist for hypermobility`, `eds clinic near me`). A knowledgeable clinician matters because hEDS is easy to under-call when symptoms are scattered — joint pain here, dizziness there, fatigue, gut issues, frequent sprains — and easy to over-call if hypermobility is the only finding. Primary care can start the workup and check for common mimics. If your main problem is joints, a rheumatologist may assess hypermobility, pain, and inflammatory or autoimmune alternatives. If there are signs of a rarer EDS type — unusual scarring, marked skin fragility, vascular or organ red flags, strong family history — a genetics service may be needed. The NHS describes this pathway as starting with a GP, with referral to rheumatology for joint problems and genetics when a rare EDS type is possible (nhs.uk).

Physiotherapists experienced in hypermobility (`eds physical therapist near me`) are central to management, not because they "put joints back," but because muscles become the active support system when ligaments are too stretchy to give reliable feedback. Good hypermobility-aware physical therapy focuses on strength, proprioception, joint control, pacing, posture, and reducing dislocations or flares without pushing you into end-range positions just because you can get there. NHS guidance and GeneReviews both place physiotherapy and occupational therapy among the practical supports that help protect joints and daily function (nhs.uk).

"Is hEDS a disability?" It can be. The diagnosis itself does not automatically decide disability status; function does. Some people with hEDS are mildly affected. Others have pain, fatigue, joint instability, dysautonomia, gut symptoms, injuries, and brain-fog days that substantially limit school, work, mobility, self-care, or normal daily routines. NHS notes that EDS can be relatively mild for some people and disabling for others, and the NCBI disability review describes EDS/HSD-related impairments as capable of limiting activities and restricting participation in work and school. Whether that qualifies in your jurisdiction is a legal or administrative decision based on documented functional limits, not just the name of the condition (ncbi.nlm.nih.gov).

Vascular EDS — the red flags you shouldn't ignore

Most people with EDS generally have a normal life span. The red-flag exception is vascular EDS (vEDS) — a rare subtype where fragile connective tissue can make blood-vessel and hollow-organ walls much easier to tear. That is why vEDS is treated differently from hypermobile EDS: it can involve unpredictable rupture of arteries or organs, including internal bleeding, intestinal perforation, stroke, and, during pregnancy or delivery, uterine rupture (medlineplus.gov).

This is not a "watch it for a few days" situation. In adults with a COL3A1 pathogenic variant, vascular rupture or dissection and gastrointestinal perforation or organ rupture are reported as presenting signs in 70% of cases; these events can be sudden and dramatic, including acute abdomen, shock, stroke, or sudden death. GeneReviews also notes that unexplained acute pain warrants immediate medical attention in vEDS (ncbi.nlm.nih.gov).

Get emergency care now if you have known or suspected vEDS — or a strong family history of it — and develop sudden, severe, unexplained chest, abdominal, back, pelvic, or head/neck pain; symptoms that feel like a heart attack or stroke; fainting or sudden collapse; signs of internal bleeding; or severe pain during pregnancy. Do not try to stretch, massage, "push through," or self-treat these symptoms. If vEDS is possible in you or your family, it is a medical priority: you need evaluation and a safety plan from clinicians who understand vascular connective-tissue disorders (ncbi.nlm.nih.gov).

Living with hEDS — management, not cure

There is no cure for EDS, so living with hEDS is mostly about management: protecting joints, building strength, pacing your energy, and treating the problems that overlap with hEDS — pain, dizziness on standing, gut symptoms, and mast-cell-type flares — as they show up in your body. Physiotherapy is usually the practical center of that plan. Not because your joints are "weak" in a character sense, but because lax connective tissue gives muscles a bigger job: they have to create stability that ligaments may not reliably provide. NHS guidance describes EDS care as symptom management with support from clinicians such as physiotherapists and occupational therapists, and specifically notes exercises to strengthen joints, avoid injury, and manage pain; Mayo Clinic similarly frames physical therapy as strengthening the muscles around joints to make them more stable (nhs.uk).

That strength work needs to be graded and joint-aware. Pushing through instability can backfire; doing nothing can make deconditioning, pain, and orthostatic symptoms worse. The sweet spot is usually slow, specific progress: core and limb strength, proprioception, balance, safer movement patterns, and adaptations for daily life. GeneReviews' hEDS management summary describes tailored exercise to improve core and extremity strength, proprioception, and joint stability, with bracing, occupational therapy, and pain management tailored to the cause and symptoms when needed; a 2023 scoping review also found therapeutic exercise and motor-function training among the better-supported physical therapy approaches for hEDS and generalized hypermobility spectrum disorder (ncbi.nlm.nih.gov).

Medication is not the foundation of hEDS care, and it should not be copied from someone else's protocol. Any medication — for pain, POTS, gut symptoms, or mast-cell symptoms — should be individualized by a clinician who knows your full history; don't self-adjust doses or borrow a regimen from another patient. This article does not recommend specific drugs or doses. NHS and Mayo Clinic both frame EDS treatment as individualized symptom management, and GeneReviews explicitly describes pain, gastrointestinal, cardiovascular/autonomic, mast-cell, and other treatments as tailored to manifestations and symptoms (nhs.uk).

For the POTS or dysautonomia layer of hEDS, heart rate patterns can be especially useful context. POTS is defined around symptoms that worsen upright plus an exaggerated heart-rate rise with standing or tilt testing; Johns Hopkins notes that diagnosis uses structured standing or tilt-table assessment with heart rate and blood pressure, and Dysautonomia International describes bedside supine-to-standing heart-rate and blood-pressure measurements when tilt testing is not available (hopkinsmedicine.org).

That is where tracking can help — not as a diagnosis, and not as treatment, but as visibility. If you can see how your heart rate and HRV shift with standing, heat, sleep, meals, stress, activity, and recovery, you and your clinician get a clearer picture of what tends to overload your autonomic system. Research in hEDS has used wearable biometric data and HRV to study day-to-day autonomic variability, and POTS research commonly treats heart rate, blood pressure, and HRV-related measures as windows into autonomic function (pubmed.ncbi.nlm.nih.gov).

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data